Vascular Endothelial Growth Factor A (VEGFA) (Middle Region) Peptide
VEGFA
Reactivité: Humain
Hôte: Synthetic
BP, WB
N° du produit ABIN5671953
150,78 €
Plus frais de livraison 40,00 € et TVA
100 μg
Destination:
France
Envoi sous 15 à 21 jours ouvrables
Aperçu rapide pour Vascular Endothelial Growth Factor A (VEGFA) (Middle Region) Peptide (ABIN5671953)
Antigène
VEGFA
(Vascular Endothelial Growth Factor A (VEGFA))
Origine
Humain
Source
Synthetic
Application
Blocking Peptide (BP), Western Blotting (WB)
-
-
Protein Region
- Middle Region
-
Séquence
- QGQHIGEMSF LQHNKCECRP KKDRARQEKK SVRGKGKGQK RKRKKSRYKS
-
Attributs du produit
- This is a synthetic peptide designed for use in combination with anti- VEGFA Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
-
-
-
Indications d'application
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Stock
- -20 °C
-
Stockage commentaire
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- VEGFA (Vascular Endothelial Growth Factor A (VEGFA))
-
Sujet
-
This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site.
Alias Symbols: VPF, VEGF, MVCD1
Protein Size: 412 -
ID gène
- 7422
-
NCBI Accession
- NM_001025366, NP_001020537
Antigène
-
Vous êtes ici:
